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Abstract 
Molecular imaging, defined as the visual representation, characterization and quantification of 
biological processes at the cellular and subcellular levels within intact living organisms, can be 
obtained by various imaging technologies, including nuclear imaging methods. Imaging of 
normal thyroid tissue and differentiated thyroid cancer, and treatment of thyroid cancer with 
radioiodine rely on the expression of the sodium iodide symporter (NIS) in these cells. NIS is 
an intrinsic membrane protein with 13 transmembrane domains and it takes up iodide into the 
cytosol from the extracellular fluid. By transferring NIS function to various cells via gene 
transfer, the cells can be visualized with gamma or positron emitting radioisotopes such as 
Tc-99m, I-123, I-131, I-124 and F-18 tetrafluoroborate, which are accumulated by NIS. They 
can also be treated with beta- or alpha-emitting radionuclides, such as I-131, Re-186, Re-188 
and At-211, which are also accumulated by NIS. This article demonstrates the diagnostic and 
therapeutic applications of NIS as a radionuclide-based reporter gene for trafficking cells and 
a therapeutic gene for treating cancers. 
Key  words:  sodium  iodide  symporter,  molecular  imaging,  radionuclide-based  imaging,  gene 
therapy, radionuclide. 
Introduction 
The ability of the thyroid gland to concentrate 
iodide has long provided the basis for diagnosis and 
therapeutic  management  of benign thyroid diseases 
and  thyroid  cancer  [1].  Thyroid  scintigraphy  with 
radioiodines or technetium-99m (Tc-99m) pertechne-
tate has played a key role in the evaluation of thyroid 
nodules with its ability of providing anatomical and 
functional  information  since  the  advent  of  modern 
endocrinology [2]. Radioiodine via an 'atomic cocktail' 
was first used medically for thyroid cancer treatment 
under the Atomic Energy Act since 1946 [3]. Thereaf-
ter,  millions  of  patients  with  benign  or  malignant 
thyroid diseases have been given radioiodine for di-
agnostic  and  therapeutic  purposes  with  successful 
outcomes. However, the uptake mechanism of radio-
iodine into thyroid tissue or thyroid cancers was not 
fully elucidated until 1996, when the sodium iodide 
symporter (NIS) was finally cloned [4]. This not only 
improved  understanding  of  thyroid  pathophysiology 
tremendously, but also offered promising molecular 
biological strategies of imaging and treatment. Clini-
cal theranostic application of NIS function using ra-
dioiodine  was  projected  to  biologic  preclinical  ex-
perimental studies after the NIS cloning. NIS expres-
sion can be imaged feasibly with simple radiotracers, 
such as radioiodines or Tc-99m. By the easy imagina-
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ble characteristic of NIS, it has been used as an imag-
ing reporter to monitor gene transfer.[5, 6] In addition 
to the potential as the imaging reporter gene, NIS has 
been  used  as  a  therapeutic  gene  to  treat  cancers 
through its ability to concentrate therapeutic doses of 
radionuclides in target cells [7-10].  
This review is mainly focused on the theranostic 
application of NIS for radionuclide-based molecular 
imaging  and  radionuclide  gene  therapy  in  in  vivo 
animal models. 
NIS  
NIS is an intrinsic plasma membrane glycopro-
tein  with  13  transmembrane  domains  that  actively 
mediates iodide transport into the thyroid follicular 
cells and several extrathyroidal tissues [11]. This pro-
tein plays an essential role in thyroid physiology by 
mediating  iodide  uptake  into  the  thyroid  follicular 
cells, a key step in thyroid hormone synthesis. NIS 
belongs  to  the  sodium/solute  symporter  family  or 
solute  carrier  family  5,  which  drives  negative-
ly-charged solutes into the cytoplasm using an elec-
trochemical  Na+  gradient  [12].  The  symporter 
co-transports two sodium ions (Na+) along with one 
iodide (I-), with the transmembrane sodium gradient 
serving as the driving force for iodide uptake; there-
fore,  NIS  functionality  is  dependent  on  the  electro-
chemical sodium gradient that is maintained by the 
oubaine-sensitive Na+/K+ATPase pump (Fig. 1) [13].  
NIS needs to be localized in the plasma mem-
brane for efficient transportation of iodide into thy-
roid  follicular  cells.  Poor  iodide  uptake  in  thyroid 
cancer cells compared to thyroid follicular cells is re-
lated to impaired targeting and retention of NIS at the 
membrane.  Membrane  localization  of  NIS  requires 
thyroid  stimulating  hormone  (TSH)  stimulation; 
through TSH deprivation, NIS is not retained at the 
membrane,  leading  to  a  decrease  in  iodide  uptake. 
Although  TSH  stimulation  is  essential  for  efficient 
NIS trafficking to plasma membrane of thyroid follic-
ular cells, it is possible that TSH-independent mecha-
nisms for the trafficking exist because non-thyroidal 
tissues also retain NIS at the membrane in the absence 
of TSH stimulation. One suggested mechanism of NIS 
targeting to the membrane is the phosphorylation of 
NIS at serine residues in the carboxy terminus. Pro-
tein-protein interaction is another suggested mecha-
nism for the trafficking. NIS contains PDZ, dileucine 
and dipeptide motifs which might be associated with 
trafficking [1, 13]. Non-thyroidal cancer tissues also 
can  express  NIS;  however,  only  20-25%  of 
NIS-positive tumors showed iodide uptake partly due 
to the intracytoplasmic location of NIS [14].  
Although expression of NIS is also detectable in 
normal  extrathyroidal  tissues  such  as  the  salivary 
glands,  gastric  mucosa  and  lactating  mammary 
glands, the expression is not regulated by TSH and is 
present at lower levels in these tissues than in thyroid 
tissue. Iodide organification is a particular and unique 
characteristic of the thyroid gland, and long-term re-
tention of iodide does not occur in the extrathyroidal 
tissues expressing NIS [15]. 
 
 
 
Figure 1. Iodide uptake function of NIS. NIS transports 2 sodium 
ions and 1 iodide ion into the cytoplasm together. The electro-
chemical  sodium  gradient  generated  by  the  oubaine-sensitive 
Na+/K+ ATPase pump provides energy for this transfer. 
  
Radiopharmaceuticals for NIS  
 NIS has marked advantages as an imaging re-
porter gene and as a therapeutic gene compared to 
other reporter or therapeutic genes due to the wide 
availability of radiopharmaceuticals and its well un-
derstood  metabolism  and  clearance  of  these  radio-
pharmaceuticals from the body [16].  
 NIS actively takes up radioiodine and Tc-99m; 
therefore, its function can be imaged with I-123, I-131, 
I-124  and  Tc-99m  [7,  15,  17].  No  issues  of  labeling 
processes and stability arise when using these radio-
pharmaceuticals, whereas they may be a major con-
cern  of  the  radiolabeled  ligands  of  other  radionu-Theranostics 2012, 2(4) 
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clide-based reporter genes, such as the dopamine D2 
receptor  or  herpes  simplex  virus  thymidine  kinase 
(HSV-tk) genes [16]. 
I-123 is produced in a cyclotron by proton irra-
diation of enriched xenon-124 (Xe-124) in a capsule, 
decays by electron capture to tellurium-123 (Te-123) 
with a half-life of 13.2 hours, and emits gamma rays 
with  predominant  energies  of  159  keV  (the  gamma 
ray is primarily used for imaging) and 127 keV. I-123, 
mainly  a  gamma  emitter,  has  a  high  counting  rate 
compared  with  I-131  and  provides  a  higher  le-
sion-to-background signal, thereby improving sensi-
tivity and imaging quality. Moreover, with the same 
administered activity, I-123 delivers an absorbed ra-
diation  dose  that  is  approximately  one-fifth  that  of 
I-131 to NIS-expressing tissues [18]. 
 I-124 is a proton-rich isotope of iodine produced 
in  a  cyclotron  by  numerous  nuclear  reactions  and 
decays to Te-124 with a half-life of 4.2 days. Its modes 
of decay are 74.4% electron capture and 25.6% posi-
tron emission. It emits gamma radiation with energies 
of 511 and 602 keV [19]. 
 I-131 is produced in a nuclear reactor by neutron 
bombardment of natural Te-127, decays by beta emis-
sion with a half-life of 8.0 days to Xe-133, and emits 
gamma rays as well. It most often (89% of the time) 
expends its 971 keV of decay energy by transforming 
into the stable Xe-131 in two steps, with gamma decay 
following rapidly after beta decay. The primary emis-
sions of I-131 decay are beta particles with a maximal 
energy of 606 keV (89% abundance, others, 248–807 
keV) and 364 keV gamma rays (81% abundance, oth-
ers 723 keV) [19]. As I-131 emits both beta and gamma 
rays,  it  can  be  used  to  image  NIS  gene  expression; 
however, it is not recommended for imaging due to 
poor  image  quality  (by  high  energy  of  the  gamma 
rays) and the high radiation burden (by the beta rays) 
compared to I-123. 
 Tc-99m,  a  metastable  nuclear  isomer  of  Tc-99, 
has a half-life of 6.0 hours and emits 140 keV gamma 
rays which is an optimal energy for scintigraphic im-
aging.  Tc-99m,  the  most  commonly  used  radionu-
clides in routine nuclear medicine imaging, is usually 
extracted  from  Tc-99m  generators  which  contain 
parent nuclide molybdenum-99 (Mo-99) [2].  
 Recently, F-18 tetrafluoroborate (F-18 TFB) was 
developed as a positron-emitting radiopharmaceuti-
cal that is actively taken up by NIS [20]. The rapid 
uptake and efflux of F-18 TFB in the rat thyroid cell 
line  parallels  the  behavior  of  Tc-99m  pertechnetate, 
which is known to be taken up in cells expressing NIS 
[20]. Uptake of F-18 TFB to thyroid follicular cells is 
stimulated by TSH and blocked by perchlorate. It was 
suggested that F-18 TFB transport occurs with little or 
no coupling to sodium transport, or that TFB occupies 
a binding site on NIS but is transported very ineffi-
ciently. 
 I-131,  rhenium-188  (Re-188),  Re-186  and  asta-
tine-211 (At-211), which emit particles from their nu-
clei,  are  used  for  radionuclide  therapy  on  cells  ex-
pressing NIS [1, 8-10, 13, 21]. Re-188 is an important 
therapeutic  radionuclide,  which  is  obtained  on  de-
mand as a carrier-free sodium perrhenate by  saline 
elution of the tungsten-188 (W-188)/Re-188 generator 
system. With a half-life of 17.0 hours and emission of a 
high-energy beta ray (maximal energy of 2.12 MeV) 
and gamma ray (155 keV, 15%) for imaging, Re-188 
offers  the  prospect  of  cost-effective  preparation  of 
radiopharmaceuticals  for  cancer  treatment  [22].  Cy-
clotron-driven neutron activator may be an alterna-
tive for on-demand supply of Re-188 [23]. 
 Currently,  At-211  is  the  most  promising  al-
pha-emitter that has been studied for cancer therapy. 
It is the heaviest halogen, with no stable isotope. It 
decays  via  a  double-branch  pathway  with  a  mean 
alpha-energy of 6.7 MeV (42% 5.9 MeV and 58% 7.5 
MeV) and a half-life of 7.2 hours. As a consequence of 
its  electron  capture  branching  to  its  daughter  polo-
nium-211, X-rays of 77 to 92 keV in sufficient abun-
dance  are  emitted,  enabling  external  imaging  (in-
cluding single photon emission computed tomogra-
phy [SPECT]) and gamma counting of blood samples 
as  additional  advantages.  However,  its  widespread 
use  in  therapeutic  doses  is  hindered  as  a  result  of 
limited availability of medium-energy cyclotrons with 
an  alpha-particle  beam  for  its  production,  which  is 
currently feasible at only a few research centers [24]. 
Table  1  summarizes  characteristics  of  radionuclides 
which can be used with NIS for diagnostic or thera-
peutic purposes. 
Use of NIS for diagnostic purposes in clinical 
nuclear medicine  
 Gamma camera imaging with radioiodine (I-131 
or I-123) can visualize metastatic lesions in differenti-
ated  thyroid  cancer  patients  who  have  undergone 
total  thyroidectomy  because  the  lesions  are  highly 
efficient at trapping circulating iodine by expression 
of NIS (Fig. 2) [25]. Radioiodine scintigraphy, once the 
mainstay  of  post-therapy  imaging  surveillance,  has 
largely been replaced by neck ultrasonography as the 
modality  of  choice  for  long-term  imaging  surveil-
lance, although it still may be used for the detection of 
occult or distant metastases, particularly in the setting 
of a newly elevated serum  thyroglobulin  level [26]. 
Routine use of  radioiodine scintigraphy for  surveil-
lance  is  not  recommended  for  low-risk  patients. 
However, it is still used in patients with intermediate Theranostics 2012, 2(4) 
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or high risk of recurrence, as well as to assess patients 
for evidence of recurrence in the setting of an elevated 
thyroglobulin level with a negative neck ultrasonog-
raphy.  Scintigraphy  performed  after  empiric  treat-
ment with high doses of I-131 is more sensitive than 
the usual diagnostic I-131 scanning [26].  
 I-124 positron emission tomography (PET) has 
higher sensitivity for the detection of thyroid cancer 
lesions  with  NIS  expression  compared  with  I-131 
whole  body  scintigraphy  due  to  lower  background 
noise and the higher resolution of PET imaging than 
gamma  camera  imaging.  Additionally,  PET  images 
can  be  fused  with  CT  and/or  magnetic  resonance 
imaging [27]. 
 Detection and localization of metastatic thyroid 
cancer lesions by radioiodine scintigraphy or PET rely 
on the expression of NIS in the cancer cells which ac-
cumulate radioiodine [27]. 
 
Table 1. Radionuclides used for diagnostic or therapeutic purposes associated with NIS. 
radioisotopes  T1/2  Emission  Most abundant energy  Medical use 
I-123  13.2 hours  gamma ray  159 keV  Diagnostic imaging (Gamma camera) 
I-124  4.2 days  positron/gamma 
ray 
511 keV/ 602 keV  Diagnostic imaging (PET) 
I-131  8.0 days  beta ray/gamma ray  606 keV/364 keV  Diagnostic imaging (Gamma camera) Therapy 
Tc-99m  6.0 hours  gamma ray  140 keV  Diagnostic imaging (Gamma camera) 
F-18  109.8 minutes  positron  511 keV  Diagnostic imaging (PET) as a form of tetra-
fluoroborate 
Re-186  90.6 hours  beta ray/gamma ray  1,070 keV/59 keV  Therapy 
Re-188  17.0 hours  beta ray/gamma ray  2,120 keV/155 keV  Therapy 
At-211  7.2 hours  alpha ray/X-ray  7,500 keV/77-92 keV  Therapy 
T1/2: half-life, PET: positron emission tomography 
 
 
 
 
 
Figure 2. A 21-year-old female who underwent total thyroidectomy due to papillary thyroid cancer. Chest simple radiography and CT 
did not demonstrate any metastatic lesion of the cancer in the neck and chest regions. However, a radioiodine whole body scan revealed 
lymph node metastases (white arrow) in the right supraclavicular area and diffuse lung metastases (black arrows). Theranostics 2012, 2(4) 
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NIS and nuclear molecular imaging  
Molecular imaging, defined as the visual repre-
sentation, characterization and quantification of bio-
logical processes at the cellular and subcellular levels 
within  intact  living  organisms,  can  be  obtained  by 
various imaging technologies, such as optical imag-
ing,  nuclear  imaging,  magnetic  resonance  imaging 
(MRI), ultrasound imaging and computed tomogra-
phy (CT) [28]. Molecular imaging has the potential to 
provide  unique  information  that  will  guarantee  the 
safety and efficacy of biotherapies which utilize anti-
bodies, bacteria or cells in humans, and also will con-
tribute to the future development of novel biothera-
pies [15]. 
With the emergence of cell therapies in regener-
ative medicine, it is important to track cells injected 
into  subjects.  In  this  context,  NIS  has  been  used  in 
preclinical studies. With transfer of the NIS gene into 
therapeutic cells such as cytotoxic T or natural killer 
cells, nuclear molecular imaging modalities can image 
the  cells  with  a  relevant  radiotracer,  such  as  I-123, 
I-124, I-131, Tc-99m or F-18 TFB. The NIS-expressing 
cells  have  been  imaged  with  planar  scintigraphy, 
SPECT or PET according to the administered radio-
tracers [15].  
Nuclear  imaging  modalities,  such  as  PET  and 
SPECT,  provide  the  3-dimensional  distribution  of 
radiopharmaceuticals  and  have  excellent  sensitivity 
and high resolution with excellent tissue penetration 
depth  [29].  These  advantages  permit  these  imaging 
techniques for use in translational research, from cell 
culture to preclinical animal models to clinical appli-
cations [28]. Both PET and SPECT give quantitative 
and non-invasive information on NIS gene expression 
or the number of NIS-expressing cells [15, 28]. 
As a gene reporter, NIS is able to be used for 
monitoring of gene and vector biodistribution and for 
trafficking of therapeutic cells [6, 15]. Contrary to the 
diagnostic application of radioiodine nuclear imaging 
using NIS gene expression for the detection of thyroid 
cancer recurrence or metastases, NIS gene transfer is a 
prerequisite for  radionuclide-based  molecular imag-
ing (Fig. 3). Non-invasive imaging of NIS expressing 
nonthyroidal cells with a gamma camera or PET upon 
viral  gene  transfer  has  been  demonstrated  feasible 
and safe in experimental animals and humans as well 
(Fig. 4) [6, 8]. 
 
 
Figure 3. Cells without NIS gene expression obtain the function of iodine uptake with NIS gene transduction by viral or non-viral vector 
delivery. The cells can be imaged by radionuclide-based molecular imaging techniques using gamma ray or positron-emitting radiotracers 
and be cleared by beta or alpha particle-emitting radionuclides. 
 Theranostics 2012, 2(4) 
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Figure 4. Visualization of macrophages expressing NIS with radionuclide-based molecular imaging. Inflammation at the right thigh (yellow 
arrow) was well visualized in F-18 FDG microPET imaging. Migration of microphages expressing NIS to the inflammation site (white 
arrow) was clearly visualized on I-124 microPET imaging [7]. 
 
Figure 5. Visualization of tumor cells expressing NIS with optical molecular imaging using I-124. Tumor xenografts of anaplastic thyroid 
cancer cells expressing NIS were well visualized on both microPET imaging (white arrows) and Cerenkov luminescence imaging (black 
arrows) after intravenous administration of I-124 [17]. 
 
Recently, I-131 and I-124, which are commonly 
used for thyroid imaging, were reported to have suf-
ficient energy to result in Cerenkov radiation that can 
be  visualized  with  sensitive  optical  imaging  equip-
ment and cells transfected with NIS gene were suc-
cessfully imaged with the radioiodines using an op-
tical imaging instrument in an in vivo animal model 
(Fig. 5) [17]. 
Radioiodine  accumulation  in  NIS-expressing 
organs  such  as  the  thyroid  is  a  deterrent  to  scinti-
graphic visualization of NIS-expressing cells in vari-
ous animal models. To remove radioiodine uptake in 
the thyroid gland and better visualize NIS-expressing 
cells, the animal can be prepared with surgical total 
thyroidectomy or radioiodine ablation before admin-
istration of the NIS-expressing cells [30]. Theranostics 2012, 2(4) 
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Use of NIS for therapeutic purposes in clini-
cal nuclear medicine  
Molecular  radionuclide-based  therapy  of  dif-
ferentiated NIS-expressing thyroid cancer with I-131 
was the cornerstone on which nuclear medicine was 
built  and  it  has  been  a  very  successful  example  of 
targeted therapy to reduce recurrence and mortality 
for almost 70 years (Fig. 6) [31, 32]. Therapeutic ap-
plication  of  I-131  for  hyperthyroidism  and  thyroid 
cancer was implemented in the early 1940s, and suc-
cess  of  the  applications  resulted  in  the  approval  of 
medical  radioisotope  use  and  initiation  of  atomic 
medicine, later re-named nuclear medicine [31, 33]. 
Radioiodine therapy for thyroid diseases  relies 
on the fact that thyroid follicular cells and differenti-
ated thyroid cancer are efficient at trapping circulat-
ing radioiodine than other tissues [25]. I-131 treatment 
has been the most preferred therapeutic modality by 
physicians for hyperthyroidism in the United States 
and it has been one of the key treatment modalities for 
differentiated  thyroid  cancers  worldwide  [34,  35]. 
However,  I-131  treatment  is  not  very  effective  in 
de-differentiated  thyroid  cancer,  which 
down-regulates NIS expression, and is meaningless in 
anaplastic  thyroid  and  medullary  thyroid  cancers, 
which  do  not  express  NIS.  One  possible  treatment 
option for de-differentiated thyroid cancer is the in-
duction  of  re-differentiation  with  differentiating 
agents such as retinoic acid and thiazolidinedione [31, 
36].  
Expression  of  NIS  is  not  uncommon  in  breast 
and stomach cancers, and some reports have shown 
visualization of primary or metastatic lesions of such 
cancers  with  radioiodine  or  Tc-99m  scintigraphy 
[37-40].  The  possibility  of  radioiodine  treatment  for 
cancers with sufficient NIS expression has been sug-
gested; however, as far as the author knows, clinical 
reports  on  such  treatment  with  successful  outcome 
have yet to be published, likely due to insufficient NIS 
expression [16]. 
Although  it  has  not  been  clinically  attempted, 
anaplastic or medullary thyroid cancers lacking NIS 
expression can be treated with I-131 after NIS gene 
transfer to the tumors. Additionally, other tumor en-
tities which do not express NIS can also be treated 
with the same strategy [31].  
 
 
 
Figure 6. A 26-year-old female who underwent total thyroidectomy due to papillary thyroid cancer. (A) Chest simple radiograph did not 
demonstrate any observable metastatic lesions of the cancer. (B) CT scan of the chest demonstrated several metastatic lesions of the 
cancer in both lung fields (white arrows). TSH-stimulated serum thyroglobulin was 65.0 ng/mL. The patient was diagnosed with metastatic 
thyroid cancer of the lung. (C) A post initial high dose I-131 treatment (150 mCi) scan revealed numerous metastatic lung lesions. (D) A 
post 2nd high dose I-131 treatment (200 mCi) scan revealed fewer but still several metastatic lung lesions (black arrows). (E, F) A post 3rd 
high dose I-131 treatment (200 mCi) scan revealed no remarkable radioiodine uptake in both lung fields and chest CT showed only tiny 
lung nodules having no clinical significance. TSH-stimulated serum thyroglobulin was 1.4 ng/mL after the third treatment. The patient had 
achieved complete remission with three times of high dose I-131 treatment and her status still remains disease-free at 7 years follow-up. 
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NIS and radionuclide gene therapy  
In addition to its imaging potential, NIS can be 
used as a therapeutic gene through its ability to con-
centrate therapeutic doses of radionuclides in target 
cells [15]. Contrary to the therapeutic application of 
I-131 using NIS gene expression for treating thyroid 
cancer recurrence or metastases, NIS gene transfer is a 
prerequisite for tumors without NIS gene expression. 
After the transfer of the NIS gene into various cancer 
cells,  they  can  be  treated  with  beta  or  alpha  parti-
cle-emitting  radionuclides  including  I-131,  Re-186, 
Re-188  and  At-211,  which  are  accumulated  via  NIS 
(Fig. 3) [31]. 
Right after NIS was cloned by Carrasco et al. in 
1996,  many  researchers  started  to  use  the  gene  for 
therapeutic purposes with I-131, and in general, the 
results  were  effective.  The  effect  of  I-131  NIS  gene 
therapy was enhanced with higher doses of I-131 and 
intervention  with  retinoic  acid  or  dexamethasone, 
which increase radioiodine uptake [41]. Transcription 
factors  such  as  Pax-8  and  TTF-1  could  induce  or 
promote  iodide  uptake  and  specifically  prolong  io-
dide retention time in cancer cells [42, 43].  
Re-188 and At-211 were also used as therapeutic 
radionuclides with NIS gene therapy to nonthyroidal 
tumors. Re-188 has advantages over I-131, as its beta 
ray energy is higher and has a shorter half-life, which 
makes  it  a  more  suitable  radionuclide  for 
NIS-expressing tumors. In addition, it is conveniently 
obtained from a W-188/Re-188 generator [44]. At-211, 
which  emits  extremely  cytotoxic  alpha-particles,  is 
known to be taken up by NIS in thyroid tissue and has 
been  used  as  a  therapeutic  radionuclide  for 
NIS-expressing tumors in cell culture and animal ex-
periments  [21,  45,  46].  In  addition  to  very  effective 
tumoricidal effects, At-211 has the advantages of al-
pha-particle’s short range and a short half-life, which 
allow  for  a  minimal  radiation  burden  to  the  sur-
rounding environment, including people [46]. 
However, single radionuclide NIS gene therapy 
might have limited therapeutic effects and can pro-
duce serious adverse effects positively related to the 
amount of administered radionuclide dose. Reducing 
the radionuclide dose for NIS gene therapy is able to 
reduce the adverse effects, but might lead to limited 
effectiveness  [47].  Combined  treatment  of  radionu-
clide  NIS  gene  therapy  with  other  therapeutic  ap-
proaches  could  be  more  efficient  to  improve  thera-
peutic  outcomes  and  can  reduce  adverse  effects  of 
radionuclide NIS gene therapy by reducing the radi-
onuclide  dose.  Chemotherapy,  genciclovir  HSV-tk 
gene therapy, immunotherapy, external beam radio-
therapy and siRNA therapy have been combined with 
radionuclide NIS gene therapy, and the results were 
almost always successful [8-10, 47]. 
Even though radionuclide NIS gene therapy has 
been shown to be effective in in vivo animal models, 
several  issues  must  be  resolved  before  this  novel 
strategy  can  be  useful  clinically.  First  of  all,  vector 
systems having safe, effective and specific NIS gene 
delivery to the tumor are needed. The optimal time 
interval  between  NIS  gene  transfer  and  therapeutic 
radionuclide administration should be determined to 
obtain the most effective therapeutic results. Organs 
that normally express NIS, such as the thyroid gland 
and the salivary glands, are inevitably damaged by 
the therapeutic radionuclide; therefore, protecting or 
managing strategies for the organs need to be devel-
oped [13, 31, 48]. 
Even though radionuclide NIS gene therapy is 
only performed in the preclinical setting at the mo-
ment, clinical trials of the treatment are likely to hap-
pen  in  the  not-too-distant  future  with  advances  in 
efficiency and safety of the therapy by close commu-
nication  between  these  basic  biological  studies  and 
clinical experiences of thyroid cancer treatment with 
I-131.  
NIS-based molecular imaging and radionu-
clide gene therapy; limitations and future 
directions  
NIS provides an advantage of both as reporter 
and therapeutic genes and therefore, NIS gene trans-
fer makes it possible to image, monitor and treat the 
tumor with appropriate radionuclides, just as in dif-
ferentiated thyroid cancer. Another advantage of NIS 
is  wide  availability  of  appropriate  diagnostic  and 
therapeutic  radiopharmaceuticals.  Although  NIS  is 
one  of  the  best  theranostic  genes,  there  are  several 
pending questions that must be answered before its 
clinical use. 
Tissues that normally express endogenous NIS 
such as the thyroid gland, salivary glands and stom-
ach, are an obstacle for NIS-based imaging or treat-
ment. Uptake of imaging radiotracers to the tissues 
conceals trafficking target cells expressing NIS which 
are  located  near  the  tissues.  Uptake  of  therapeutic 
radionuclides to the normal tissues can damage the 
organs  and  may  reduce  tracer  uptake  to  the  target 
cells expressing exogenous NIS.  
Retention time of radioiodine is generally short 
in NIS-transduced cells by rapid washout of the radi-
oiodine, therefore absorbed dose and toxicity to the 
target  cells  might  be  limited  and  it  precludes  suc-
cessful radioiodine NIS gene therapy. To prolong the 
retention  time,  drugs  such  as  lithium  carbonate,  or Theranostics 2012, 2(4) 
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co-transfer of the thyroid peroxidase gene was intro-
duced, however, results were conflicting and not very 
effective  [13].  Co-transfer  of  the  thyroglobulin  gene 
was  also  suggested  to  increase  retention  time  [42]. 
Efflux of iodine from the cell is known to be related to 
pendrin,  SLC5A8  and  ClCn5,  and  even  though  not 
verified  by  experiments,  down-regulation  of  these 
proteins  can  delay  iodine  efflux  from  the  cell  [42]. 
Ablation of the thyroid gland and low iodine diet are 
able to prolong the retention time in NIS transduced 
tumor cells, however applicability of this strategy is 
limited in a clinical situation. It can be feasibly applied 
only  in  thyroid  cancer  patients  receiving  previous 
thyroidectomy.  Enhancement  of  radioiodine  uptake 
by  up-regulation  of  NIS  expression  has  been  tried 
with drugs such as retinoic acid or dexamethasone, 
troglitazone and external radiation [49, 50]. Histone 
deacetylase inhibitors (e.g. depsipeptide, trichosatin A 
and  valproic  acid)  and  demethylating  agents 
(5-azacytidine) have been used to restore endogenous 
NIS expression [1]. In addition to increasing radiation 
dose  to  the  NIS  expressing  cells,  radiosensitization 
can enhance the biological effect of the same radiation 
dose. DNA damage repair inhibitors revealed a ther-
apeutic  benefit  with  radionuclide  NIS  gene  therapy 
[51].  Further  studies  are  needed  for  validation  and 
optimization of the  pharmacological approaches for 
prolonging the retention time, delaying iodine efflux, 
restoring/up-regulation  of  NIS  expression  and  en-
hancing radiosensitization before practical use.  
Several  new  diagnostic  or  therapeutic  radio-
pharmaceuticals for NIS were recently studied. Cells 
expressing NIS can be imaged with F-18 FTB PET in-
stead of radioiodine scintigraphy and be treated more 
effectively with Re-188, Re-186 or At-211 instead of 
I-131. Some of the radiopharmaceuticals are not suit-
able at present due to scarce availability and nontriv-
ial safety issues related to their production and han-
dling. Technical advancement of the production and 
handling skills for the radiopharmaceuticals is war-
ranted.  
With administration of I-131, the thyroid gland 
takes up I-131 and retains it within the gland for a 
long time by organification of the radioiodine.  This 
will end in permanent hypothyroidism by radioabla-
tion of normal thyroid tissue. The salivary gland also 
accumulates  the  radionuclide  and  xerostomia  can 
occur by radiation sialoadenitis related to uptake of 
the  radionuclide.  To  maintain  sufficient  radioiodine 
uptake to the extrathyroidal cancer tissues expressing 
NIS, uptake of radioiodine to the thyroid gland can be 
suppressed  by  thyroid  hormone  replacement  and 
antithyroidal drugs [52]. Stable iodine administration 
before administration of radioiodine can reduce radi-
oiodine to the gland as well [13]. Radioiodine uptake 
in the salivary gland can be expelled by manual mas-
sage of the gland and may reduce incidence of xero-
stomia related to radiation-induced sialoadenitis [53]. 
Strategies for preventing  or reducing side effects to 
normal tissues expressing NIS by  radionuclides up-
take must be developed and optimized before com-
mon  clinical  application  of  NIS-based  radionuclide 
theranostics. 
Conclusions  
Although diagnostic and therapeutic use of the 
NIS gene began in clinics more than half a century 
ago,  understanding  of  the  biology  of  NIS  has  been 
advancing  rapidly  the  last  two  decades.  NIS-based 
molecular  imaging  and  radionuclide  gene  therapy, 
cutting edge technologies in molecular imaging and 
gene therapy arenas, were born with imitation of di-
agnostic and therapeutic applications in the field of 
clinical  thyroid  practice.  With  fast  advancement  of 
molecular imaging and gene therapy with active re-
search, these bench technologies are likely to be used 
in the clinical setting in the near future. 
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